Latest news
Sarepta Therapeutics Navigates FDA Hold on Elevidys in Expanding DMD Market - Streetwise ReportsStreetwise Reports · Thu, 06 Aug 2026 09:41:48 GMTMigraine Biotech Doses First Patient in Phase 2b EVO756 Trial - Streetwise ReportsStreetwise Reports · Thu, 06 Aug 2026 09:41:48 GMTPFAS Treatment System Processes 2 Million Gallons at New Jersey Site - Streetwise ReportsStreetwise Reports · Tue, 04 Aug 2026 14:59:36 GMTEvommune Doses First Patient in Migraine Trial - Streetwise ReportsStreetwise Reports · Mon, 03 Aug 2026 07:00:00 GMTSarepta Therapeutics (SRPT) Appoints New CEO, Shares Surge 7% - GuruFocusGuruFocus · Mon, 27 Jul 2026 16:28:23 GMT